EP2347009A4 - GENETIC AND PROTEIN TARGETS EXPRESSED BY GENES REPRESENTING BIOMARKER PROFILES AND SIGNATURE SETS BY TYPE OF TUMORS - Google Patents

GENETIC AND PROTEIN TARGETS EXPRESSED BY GENES REPRESENTING BIOMARKER PROFILES AND SIGNATURE SETS BY TYPE OF TUMORS

Info

Publication number
EP2347009A4
EP2347009A4 EP09821173A EP09821173A EP2347009A4 EP 2347009 A4 EP2347009 A4 EP 2347009A4 EP 09821173 A EP09821173 A EP 09821173A EP 09821173 A EP09821173 A EP 09821173A EP 2347009 A4 EP2347009 A4 EP 2347009A4
Authority
EP
European Patent Office
Prior art keywords
tumors
genetic
type
protein targets
biomarker profiles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09821173A
Other languages
German (de)
French (fr)
Other versions
EP2347009A2 (en
Inventor
Hoff Daniel D Von
Robert J Penny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caris Life Sciences Inc
Original Assignee
Caris MPI Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caris MPI Inc filed Critical Caris MPI Inc
Priority to EP16158951.0A priority Critical patent/EP3075864A1/en
Publication of EP2347009A2 publication Critical patent/EP2347009A2/en
Publication of EP2347009A4 publication Critical patent/EP2347009A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30—Data warehousing; Computing architectures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Databases & Information Systems (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioethics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
EP09821173A 2008-10-14 2009-10-14 GENETIC AND PROTEIN TARGETS EXPRESSED BY GENES REPRESENTING BIOMARKER PROFILES AND SIGNATURE SETS BY TYPE OF TUMORS Withdrawn EP2347009A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP16158951.0A EP3075864A1 (en) 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10533508P 2008-10-14 2008-10-14
US10692108P 2008-10-20 2008-10-20
PCT/US2009/060630 WO2010045318A2 (en) 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP16158951.0A Division EP3075864A1 (en) 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Publications (2)

Publication Number Publication Date
EP2347009A2 EP2347009A2 (en) 2011-07-27
EP2347009A4 true EP2347009A4 (en) 2012-05-30

Family

ID=42107198

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16158951.0A Withdrawn EP3075864A1 (en) 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EP09821173A Withdrawn EP2347009A4 (en) 2008-10-14 2009-10-14 GENETIC AND PROTEIN TARGETS EXPRESSED BY GENES REPRESENTING BIOMARKER PROFILES AND SIGNATURE SETS BY TYPE OF TUMORS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP16158951.0A Withdrawn EP3075864A1 (en) 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Country Status (6)

Country Link
US (5) US20100113299A1 (en)
EP (2) EP3075864A1 (en)
CN (2) CN106153918A (en)
CA (1) CA2739675C (en)
IL (1) IL212349A0 (en)
WO (1) WO2010045318A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108421044A (en) 2005-02-03 2018-08-21 综合医院公司 The method for treating gefitinib resistant cancer
BRPI0618042A2 (en) 2005-11-04 2011-08-16 Wyeth Corp uses of a rapamycin and herceptin, product, pharmaceutical package, and, pharmaceutical composition
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2007137187A2 (en) * 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
CN102641270A (en) 2008-06-17 2012-08-22 惠氏有限责任公司 Antineoplastic combinations containing HKI-272 and vinorelbine
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimens containing neratinib for the treatment of cancer
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
CA2787048C (en) 2010-01-13 2021-06-22 Wyeth Llc A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor
RU2565550C2 (en) 2010-09-24 2015-10-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Direct capture, amplification and sequencing of target dna using immobilised primers
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
CN102094084B (en) * 2010-11-24 2012-09-19 中山大学附属第三医院 Fluorescent quantitative PCR method, kit and application for detecting EphA2 gene expression
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US20130254547A1 (en) * 2012-03-23 2013-09-26 International Business Machines Corporation Encrypted transmission to and storage of surprisal data
US10353869B2 (en) 2012-05-18 2019-07-16 International Business Machines Corporation Minimization of surprisal data through application of hierarchy filter pattern
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN114606309A (en) 2014-11-05 2022-06-10 威拉赛特公司 Diagnostic system and method using machine learning and high-dimensional transcription data
IL318703A (en) 2015-06-29 2025-03-01 Caris Science Inc Therapeutic oligonucleotides
EP3328873B1 (en) 2015-07-28 2025-09-17 Caris Science, Inc. Targeted oligonucleotides
WO2017161357A1 (en) 2016-03-18 2017-09-21 Caris Science, Inc. Oligonucleotide probes and uses thereof
CA3025486A1 (en) 2016-05-25 2017-11-30 Caris Science, Inc. Oligonucleotide probes and uses thereof
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
AU2018310987A1 (en) 2017-08-04 2020-02-27 Decipher Biosciences, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
WO2020113237A1 (en) 2018-11-30 2020-06-04 Caris Mpi, Inc. Next-generation molecular profiling
KR20260043144A (en) 2019-12-02 2026-03-31 캐리스 엠피아이, 아이엔씨. Pan-cancer platinum response predictor
TWI913719B (en) 2024-04-19 2026-02-01 宏碁股份有限公司 Feature creation method
WO2025255578A1 (en) 2024-06-07 2025-12-11 Caris Mpi, Inc. Dual-modality models for digital pathology

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013431A (en) * 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
US5610281A (en) * 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US5710001A (en) * 1994-08-12 1998-01-20 Myriad Genetics, Inc. 17q-linked breast and ovarian cancer susceptibility gene
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5837492A (en) * 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
EP0785216B2 (en) * 1995-12-18 2006-06-07 The University of Utah Research Foundation Chomosome 13-linked breast cancer susceptibility gene BRCA2
US5895748A (en) * 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
US6150514A (en) * 1997-04-09 2000-11-21 University Of Utah Research Foundation 14 Kilobase deletion in the promoter region of BRCA1 in a breast cancer family
WO2000024940A1 (en) * 1998-10-28 2000-05-04 Vysis, Inc. Cellular arrays and methods of detecting and using genetic disorder markers
CN1231761C (en) * 1998-12-23 2005-12-14 梅德塞克股份有限公司 Assay to detect binding partner
US6613510B2 (en) * 1999-04-28 2003-09-02 Mayo Foundation For Medical Education And Research Methods and probe sets for determining prostate cancer prognosis
EP1283906A4 (en) * 2000-03-31 2005-04-27 Univ Southern California EPIGENETIC SEQUENCES FOR DININGENEROKARZINOME
US6812023B1 (en) * 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
DE10043591A1 (en) * 2000-09-01 2002-03-14 Max Delbrueck Centrum Procedure for the detection of resistance profiles of tissues and cell lines
US8613907B2 (en) * 2000-10-12 2013-12-24 University Of Rochester Compositions that inhibit proliferation of cancer cells
WO2002044715A1 (en) * 2000-11-28 2002-06-06 Surromed, Inc. Methods for efficiently minig broad data sets for biological markers
DE60235088D1 (en) * 2001-07-05 2010-03-04 Taiho Pharmaceutical Co Ltd DNA ARRAYS FOR MEASURING SENSITIVITY AGAINST AN ANTICREMENT
US7529685B2 (en) * 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
WO2003056036A2 (en) * 2001-12-21 2003-07-10 The Wellcome Trust Genes
JP3481231B2 (en) * 2002-03-05 2003-12-22 三洋電機株式会社 Organic electroluminescent display device and method of manufacturing the same
DK2258872T3 (en) * 2002-03-13 2013-11-18 Genomic Health Inc Gene expression profiling in tumor tissue biopsies
AU2003253629A1 (en) * 2002-06-07 2003-12-22 Myriad Genetics, Inc Large deletions in human brca1 gene and use thereof
DE60200248T2 (en) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Procedure for solution-based diagnosis
AT500648B1 (en) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie SET FOR THE TREATMENT OF CANCER PATIENTS
JP4939055B2 (en) * 2002-11-13 2012-05-23 トマス ジェファソン ユニバーシティ Compositions and methods for diagnosis and treatment of cancer
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
WO2004089073A2 (en) * 2003-04-03 2004-10-21 Genpath Pharmaceuticals, Incorporated Inducible breast cancer model
SI1613350T1 (en) * 2003-04-09 2009-08-31 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
US7361460B2 (en) * 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases
US20050084913A1 (en) * 2003-04-22 2005-04-21 Maxygen, Inc. Novel tumor-associated antigens
CA2527321A1 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7319007B2 (en) * 2003-06-12 2008-01-15 Pomeranian Academy Of Medicine Determining a predisposition to cancer
WO2004112575A2 (en) * 2003-06-20 2004-12-29 Amgen Inc. Gene amplification and overexpression in cancer
EP3330875B1 (en) * 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
EP1980629A3 (en) * 2003-08-28 2008-12-17 Ipsogen Identification of an erbb2 gene expression signature in breast cancers
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
EP3611273A1 (en) * 2004-03-31 2020-02-19 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
US7871769B2 (en) * 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
WO2005111211A2 (en) * 2004-05-14 2005-11-24 Rosetta Genomics Ltd. Micronas and uses thereof
EP2527460B1 (en) * 2004-05-27 2014-12-24 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
WO2006039563A2 (en) * 2004-09-30 2006-04-13 Epigenomics Ag Method for providing dna fragments derived from an archived sample
WO2006050475A2 (en) * 2004-11-03 2006-05-11 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with neurological diseases
US7442507B2 (en) * 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
EP1874471A4 (en) * 2005-03-16 2008-12-10 Sidney Kimmel Cancer Ct METHODS AND COMPOSITIONS FOR PREDICTING CANCER DEATH AND CANCER SURVIVAL OF PROSTATE USING GENE EXPRESSION SIGNATURES
US20090061422A1 (en) * 2005-04-19 2009-03-05 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP2386854A1 (en) * 2005-04-19 2011-11-16 Prediction Sciences LLC Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP1722230A3 (en) * 2005-04-27 2009-05-27 MPB MelTec Patent- und Beteiligungsgesellschaft mbH Method for detection of a disease-specific combinatorial molecular pattern motif in a tissue sample of a patient's skin
WO2006121991A2 (en) * 2005-05-06 2006-11-16 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of breast cancer
US20070020657A1 (en) * 2005-05-20 2007-01-25 Grebe Stefan K Methods for detecting circulating tumor cells
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007072220A2 (en) * 2005-09-12 2007-06-28 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing cancer
WO2007038792A2 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
US20090226902A1 (en) * 2005-10-12 2009-09-10 Hemmo Arjan Drexhage Method to Diagnose or Screen for Inflammatory Diseases
US7723112B2 (en) * 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20090215642A1 (en) * 2005-12-09 2009-08-27 Knudson Alfred G Methods and Compositions for Assessing Alterations in Gene Expression Patterns in Clinically Normal Tissues Obtained from Heterozygous Carriers of Mutant Genes Associated with Cancer and Methods of Use Thereof
JP2007175021A (en) * 2005-12-28 2007-07-12 Sysmex Corp Lymph node metastasis marker of colon cancer
US7593913B2 (en) * 2006-01-11 2009-09-22 Siemens Medical Solutions Usa, Inc. Systems and method for integrative medical decision support
EP1999472A2 (en) * 2006-03-09 2008-12-10 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US20090098538A1 (en) * 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy
US7890267B2 (en) * 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
US7901885B2 (en) * 2006-05-09 2011-03-08 Dsm Ip Assets B.V. Genes and markers in type 2 diabetes and obesity
WO2007137187A2 (en) * 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
MX2008015581A (en) * 2006-06-05 2008-12-17 Genentech Inc Extending survival of cancer patients with elevated levels of egf or tgf-alpha.
US8288369B2 (en) * 2006-06-27 2012-10-16 University Of South Florida Delta-tocotrienol treatment and prevention of pancreatic cancer
US20080014598A1 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Phospho-specific antibodies to pi3k regulatory subunit and uses thereof
US7999080B2 (en) * 2006-07-13 2011-08-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
CN101501695A (en) * 2006-08-11 2009-08-05 皇家飞利浦电子股份有限公司 Systems and methods for associating nucleic acid profiles and proteomic profiles with healthcare protocols and guidelines in a decision support system
EP1892303A1 (en) * 2006-08-22 2008-02-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods for identifying therapeutical targets in tumors and for determining and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung
US20090280493A1 (en) * 2006-09-08 2009-11-12 Siemens Healthcare Diagnostics Inc. Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia
CA2667737A1 (en) * 2006-10-27 2008-05-02 Julius Gudmundsson Cancer susceptibility variants on chr8q24.21
AU2007334343A1 (en) * 2006-12-15 2008-06-26 Ordway Research Institute, Inc. Treatments of therapy-resistant diseases comprising drug combinations
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
US20080226645A1 (en) * 2007-01-10 2008-09-18 Wyeth Methods and compositions for assessment and treatment of asthma
WO2008092153A2 (en) * 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
WO2008092164A2 (en) * 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Methods of detecting autoantibodies for diagnosing and characterizing disorders
EP2129791A4 (en) * 2007-02-26 2010-07-28 Wayne John Cancer Inst USEFULNESS OF B-RAF DNA MUTATION IN THE DIAGNOSIS AND TREATMENT OF CANCER
CN101932938B (en) * 2007-11-30 2014-08-27 克雷特诊疗服务公司 Tle3 as a marker for chemotherapy
ES2482692T3 (en) * 2008-05-12 2014-08-04 Genomic Health, Inc. Tests to predict the receptivity of cancer patients to chemotherapy treatment options
US20100069298A1 (en) * 2008-09-16 2010-03-18 Robert Penny Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GYURKOCZA BOGLARKA ET AL: "Antileukemic activity of shepherdin and molecular diversity of Hsp90 inhibitors", JOURNAL OF THE NATIONAL CANCER INSTITUTE (CARY), vol. 98, no. 15, August 2006 (2006-08-01), pages 1068 - 1077, XP002672777, ISSN: 0027-8874 *
PADUANO FRANCESCO ET AL: "Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 1, January 2006 (2006-01-01), pages 179 - 186, XP002672776, ISSN: 1535-7163 *

Also Published As

Publication number Publication date
US20120015843A1 (en) 2012-01-19
CN102232117A (en) 2011-11-02
WO2010045318A3 (en) 2010-08-19
WO2010045318A2 (en) 2010-04-22
EP2347009A2 (en) 2011-07-27
US20140149136A1 (en) 2014-05-29
CA2739675A1 (en) 2010-04-22
US20100113299A1 (en) 2010-05-06
CA2739675C (en) 2020-12-01
EP3075864A1 (en) 2016-10-05
CN106153918A (en) 2016-11-23
US20140057986A1 (en) 2014-02-27
IL212349A0 (en) 2011-06-30
US20140149137A1 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
IL212349A0 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
BRPI0916229A2 (en) signatures and determinants pcs associated with prostate cancer and methods of using them
WO2012030840A9 (en) Gene signatures for cancer diagnosis and prognosis
PL2800811T3 (en) Methods and compositions for targeted RNA modification of target DNA and for modulation of transcription of targeted RNA
IL226272A (en) Identification of genetic or molecular aberrations related to cancer
ZA201305024B (en) Colon cancer gene expression signatures and methods of use
EP2361988A4 (en) MOLECULAR MARKER OF CANCER STRAIN CELL
MX390699B (en) COMPOSITIONS AND METHODS FOR INHIBITION OF APOLIPOPROTEIN C-III (APOC3) GENES.
SG11201402402SA (en) Nucleic acid fragment binding to target protein
BR112013002299A2 (en) method of capturing and sequencing a nucleic acid target molecule and method of determining the methylation status of a genome DNA fragment
BRPI0811755A2 (en) SPECIFIC AMPLIFICATION OF TUMOR SPECIFIC DNA SEQUENCE.
CY1117858T1 (en) Oligonucleotides for the induction of a change in the sequence of a molecule-target RNA present in a living cell
PL2188379T3 (en) Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2542414A4 (en) MICRO-PRINTER OF SHEETS
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
GB0811413D0 (en) Gene expression signatures for lung cancers
EP2744919A4 (en) Gene signatures for lung cancer prognosis and therapy selection
BRPI0916440A2 (en) compositions and methods for inhibiting tgf-beta receptor gene expression
BR112013004044A2 (en) compositions and methods for quantifying a nucleic acid sequence in a sample.
ATE534738T1 (en) MIR-126-REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTIONS
DK2611915T3 (en) Nucleic acid fragments from a ribosomal protein promoter to enhance gene expression
GB0811500D0 (en) Method of determining DNA copy number
BRPI0909063A2 (en) Target amplification and primer sequencing comprising triple forming monomer units.
WO2008137089A3 (en) Gene signature of early hypoxia to predict patient survival
BRPI0910448A2 (en) synthesis of improved binders and modified tactics

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110516

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G06F 19/00 20110101ALI20120412BHEP

Ipc: C12N 15/12 20060101ALI20120412BHEP

Ipc: C12Q 1/68 20060101AFI20120412BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120426

17Q First examination report despatched

Effective date: 20130919

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160308